AN2 Therapeutics Stock Price, News & Analysis
ANTX
NASDAQ
Company Description
Welcome to the overview page for AN2 Therapeutics (ANTX), where you can find comprehensive stock information and company updates.
Explore the latest news on strategic partnerships, quarterly and annual financial results, and regulatory filings including SEC reports and insider transactions.
Visualize performance trends using the interactive price chart, and keep track of upcoming events such as earnings calls, dividend dates, and investor conferences.
Stock Performance
Latest News
SEC Filings
Insider Radar
Net Sellers
90-Day Summary
0
Shares Bought
3,584
Shares Sold
2
Transactions
Most Recent Transaction
Eizen Joshua M
(See Remarks)
sold
2,819 shares
@ $1.14
on Nov 4, 2025
Based on SEC Form 4 filings over the last 90 days.
Financial Highlights
$0
Revenue (TTM)
-$51,321,000
Net Income (TTM)
-$1.72
-$49,257,000
Operating Cash Flow
8.43
-$56,788,000
Upcoming Events
MAY
01
May 1, 2026 - August 31, 2026
Clinical
Oncology program development
Second boron-based oncology program enters development
JAN
01
January 1, 2027
Clinical
Phase 2 data readout
Anticipated Phase 2 proof-of-concept data for AN2-502998 in chronic Chagas disease
Short Interest History
Last 12 Months
Loading short interest data...
Days to Cover History
Last 12 Months
Loading days to cover data...
Frequently Asked Questions
What is the current stock price of AN2 Therapeutics (ANTX)?
The current stock price of AN2 Therapeutics (ANTX) is $1.14 as of January 1, 2026.
What is the market cap of AN2 Therapeutics (ANTX)?
The market cap of AN2 Therapeutics (ANTX) is approximately 31.2M. Learn more about what market capitalization means .
What is the revenue (TTM) of AN2 Therapeutics (ANTX) stock?
The trailing twelve months (TTM) revenue of AN2 Therapeutics (ANTX) is $0.
What is the net income of AN2 Therapeutics (ANTX)?
The trailing twelve months (TTM) net income of AN2 Therapeutics (ANTX) is -$51,321,000.
What is the earnings per share (EPS) of AN2 Therapeutics (ANTX)?
The diluted earnings per share (EPS) of AN2 Therapeutics (ANTX) is -$1.72 on a trailing twelve months (TTM) basis. Learn more about EPS .
What is the operating cash flow of AN2 Therapeutics (ANTX)?
The operating cash flow of AN2 Therapeutics (ANTX) is -$49,257,000. Learn about cash flow.
What is the current ratio of AN2 Therapeutics (ANTX)?
The current ratio of AN2 Therapeutics (ANTX) is 8.43, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.
What is the operating income of AN2 Therapeutics (ANTX)?
The operating income of AN2 Therapeutics (ANTX) is -$56,788,000. Learn about operating income.